Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 1;25(12):4371-4380.
doi: 10.31557/APJCP.2024.25.12.4371.

Analysis of the Effectiveness and Coverage of Breast, Cervical, and Colorectal Cancer Screening Programs in Kazakhstan for the Period 2021-2023: Regional Disparities and Coverage Dynamics

Alfiya Shamsutdinova  1 , Gulnara Kulkayeva  2 , Zhadyra Karashutova  2 , Baimakhan Tanabayev  3 , Shynar Tanabayeva  1 , Anel Ibrayeva  1 , Ildar Fakhradiyev  1   4
Affiliations

Analysis of the Effectiveness and Coverage of Breast, Cervical, and Colorectal Cancer Screening Programs in Kazakhstan for the Period 2021-2023: Regional Disparities and Coverage Dynamics

Alfiya Shamsutdinova et al. Asian Pac J Cancer Prev. .

Abstract

Background: Cancer screening is a crucial component in the fight to reduce cancer incidence and mortality. Currently, the WHO recommends highly effective cancer screening programs, including screening for cervical cancer (CC), breast cancer (BC), and colorectal cancer (CRC). Despite the implementation of a cancer screening program since 2014, an evaluation of the effectiveness of BC, CC, and CRC screening in the Kazakhstan has not yet been conducted. Study aimed to assess the effectiveness and coverage of BC, CC, and CRC screening in the Republic of Kazakhstan during the period from 2021 to 2023.

Methods: Data for the retrospective analysis were extracted from the "Healthcare Statistics" database. Data on participants eligible for screening (n=8,167,184) for BC, CC, and CRC were included in the analysis.

Results: In 2023, there was a noticeable decrease in the number of detected cases of CC (1.7) compared to previous years. The detection rates for BC (14) and CRC (around 1) per 100,000 population in 2023 remained almost at the same level as in previous years. The detection rate for BC was 0.74% in 2021, followed by a decline to 0.59% in 2022. In 2023, there was an increase to 1.69%. As for CC, the detection rate was 0.70% in 2021, it increased to 0.77% in 2022, but then decreased again to 0.53% in 2023. CRC shows a steady decline in detection rates. In 2021, the detection rate was 4.23%, then it dropped to 3.64% in 2022, and continued to decrease to 3.28% in 2023.

Conclusions: The data for 2021-2023 underscore the necessity for continuous monitoring, analysis, and adaptation of screening strategies, taking into account regional peculiarities and new challenges, such as the pandemic. Ensuring high screening coverage for BC, CC, and CRC is a key factor for the early detection and effective treatment of these diseases.

Keywords: Efficiency; Neoplasms; national cancer screening; screening coverage.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Quantitative Indicators for BC, CC, and CRC Screening During the Period 2021-2023.
Figure 2
Figure 2
Main Correlational Relationships Between Year, Screening, and Diagnosis for BC, CC, and CRC.
Figure 3
Figure 3
Regression Analysis of the Relationship between Breast Cancer Screening Coverage and the Number of Detected Cases.
Figure 4
Figure 4
Regression Analysis of the Relationship between the Coverage of Screening for Cervical Cancer and the Number of Detected Cases.
Figure 5
Figure 5
Regression Analysis of the Relationship between CRC Screening Coverage and the Number of Detected Cases.
Figure 6
Figure 6
Detection Rates for BC, CC, and CRC from 2021 to 2023
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. - PubMed
    1. Pinsky PF. Principles of Cancer Screening. Surg Clin North Am. 2015;95(5):953–66. - PMC - PubMed
    1. Sarma EA, Silver MI, Kobrin SC, Marcus PM, Ferrer RA. Cancer screening: health impact, prevalence, correlates, and interventions. Psychol Health. 2019;34(9):1036–72. - PubMed
    1. WHO Regional Office for Europe A short guide to cancer screening: increase effectiveness, maximize benefits and minimize harm. 2022. Available from: https://apps.who.int/iris/handle/10665/351396.
    1. Torres-De La Roche LA, Campo R, Devassy R, Di Spiezio Sardo A, Hooker A, Koninckx P, et al. Adhesions and Anti-Adhesion Systems Highlights. Facts Views Vis Obgyn. 2019;11(2):137–49. - PMC - PubMed

MeSH terms